A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.
BioXcel Therapeutics Inc
BioXcel Therapeutics Inc
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
BioXcel Therapeutics Inc
FDA Office of Orphan Products Development
National Institutes of Health Clinical Center (CC)
Point Therapeutics
Point Therapeutics